Diagnosis Place of delivery Proforma

1. Background & Scope 3

Birmingham Children s Hospital Primary treatment centre (PTC) list of protocols and guidelines which contain approved cytotoxic chemotherapy regimens Updated 9 th June 2016 (Jason Patel) Contents 1. Background

Open / Closed to Recruitment. POSCU Involvement. Diagnosis Trial Oral Chemo Protocol Title Bone

This list covers the Principal Treatment Centre (Alder Hey) and POSCUs including community services. It covers solid tumour oncology and haemato oncology clinical management protocols and agreed chemotherapy

An international clinical program for the diagnosis and treatment of children, adolescents and young adults with ependymoma

This list covers the Principal Treatment Centre (Alder Hey) and POSCUs including community services. It covers solid tumour oncology and haemato-oncology clinical management protocols and agreed chemotherapy

CURRENTLY ENROLLING ONCOLOGY TREATMENT STUDIES (as of 4/27/2017)

CURRENTLY ENROLLING ONCOLOGY TREATMENT STUDIES (as of 4/27/2017) Leukemia AALL0932 closed after Induction Treatment of Patients with Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized

All India Institute of Medical Sciences, New Delhi, INDIA. Department of Pediatric Surgery, Medical Oncology, and Radiology

All India Institute of Medical Sciences, New Delhi, INDIA Department of Pediatric Surgery, Medical Oncology, and Radiology Clear cell sarcoma of the kidney- rare renal neoplasm second most common renal

Lancet 2008; 372 : CDF. N Engl J Med Aug 28;349(9): J Clin Oncol May 15;19(10): Cancer Nov 1;113(9):2471-7

Tumour Group: UROLOGY Renal Palliative Sunitinib 1 st line therapy Lancet. 1999 Jan 2;353(9146):14-7. Pazopanib 1 st line therapy J Clin Oncol. 2010 28(06):1061-1068 Everolimus 2 nd or 3 rd line in adv./metas.rcc

RARE TUMORS OF INFANCY. RAJKUMAR VENKATRAMANI, MD, MS Director, Rare Tumors Program, Texas Children s Hospital

RARE TUMORS OF INFANCY RAJKUMAR VENKATRAMANI, MD, MS Director, Rare Tumors Program, Texas Children s Hospital OBJECTIVES Review the epidemiology and clinical presentation of soft tissue sarcomas in infancy.

NICaN Bone and Soft Tissue SACT protocols. 17/2/ H McCarty Reviewed and updated

Reference No: Title: Auth(s) Systemic anti cancer therapy (SACT) clinical management guidelines f bone and soft tissue sarcoma Dr Heather McCarty Consultant Clinical Oncologist on behalf of the Sarcoma

Patient Management Policy

London and South East Patient Management Policy This document has been compiled by members of the London and South East and approved by all consultants. It will be reviewed and updated annually. The purpose

CURRENTLY ENROLLING ONCOLOGY TREATMENT STUDIES (as of )

Leukemia AALL0932 closed after Induction CURRENTLY ENROLLING ONCOLOGY TREATMENT STUDIES (as of 10.10.2017) Treatment of Patients with Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized

ASSESSMENT OF THE PAEDIATRIC NEEDS CHEMOTHERAPY PRODUCTS (PART I) DISCLAIMER

European Medicines Agency Evaluation of Medicines for Human Use London, September 2006 Doc. Ref.: EMEA/384641/2006 ASSESSMENT OF THE PAEDIATRIC NEEDS CHEMOTHERAPY PRODUCTS (PART I) DISCLAIMER The Paediatric

Exhibit B United States Patent Application 20020012663 Kind Code A1 Waksal, Harlan W. January 31, 2002 Treatment of refractory human tumors with epidermal growth factor receptor antagonists Abstract A

Emetogenicity level 1. Emetogenicity level 2

Emetogenicity level 1 15 mins Pre-Chemo Maxalon 10mg po During chemo and Post Chemo 3 days Maxalon10mg po 8 hourly Increase Maxalon 20mg po 8 hourly Change to Cyclizine 50mg po 8 hourly 3 days If nausea

Lessons from treatment of pediatric sarcomas at difficult sites. Dr. Andrea Ferrari Pediatric Oncology Unit Istituto Nazionale Tumori, Milan, Italy

Lessons from treatment of pediatric sarcomas at difficult sites Dr. ndrea Ferrari Pediatric Oncology Unit stituto Nazionale Tumori, Milan, taly Disclosure slide have no potential conflicts of interest

Standard Regimens for Haematology

Regimens for Haematology ChlVPP Chlorambucil 6mg/m 2 PO D1 to 14 Vinblastine 6mg/m 2 (max 10mg) IV on D1 & 8 Procarbazine 100mg/m 2 PO on D1 to 14 Prednisolone 40mg PO D1 to 14 ABVD Doxorubicin 25mg/m

West of Scotland Cancer Network Guideline for Managing Chemotherapy Induced Nausea and Vomiting

West of Scotland Cancer Network Guideline for Managing Chemotherapy Induced Nausea and Vomiting Definitions Acute nausea and vomiting Delayed nausea and vomiting Anticipatory nausea and vomiting Initial

CCG-3891 LONG TERM OUTCOME FOR CHILDREN WITH HIGH RISK NEUROBLASTOMA Additional Information on Corrected Overall Survival Results April 10, 2014

Group Chair Peter C. Adamson, M.D. adamson@email.chop.edu Group Vice Chair Susan Blaney, M.D. smblaney@txch.org Chief Operating Officer Elizabeth O Connor, M.P.H. econnor@childrensoncology group.org Chief

Medical Therapies in Ovarian Cancer The Arabic Perspectives. Mezghani Bassem -Tunisia

Tunisian Health System: Social Welfare with a Public insurance for all citizens including Indigent persons. (± Additional private insurance) Choice: Public Hospital/Private Clinics (Indigents Public H)

OVERVIEW OF COMMENTS RECEIVED ON LIST OF PAEDIATRIC NEEDS ONCOLOGY I (CYTOTOXIC THERAPY)

European Medicines Agency Evaluation of Medicines for Human Use London, September 2006 Doc. Ref. OVERVIEW OF COMMENTS RECEIVED ON LIST OF PAEDIATRIC NEEDS ONCOLOGY I (CYTOTOXIC THERAPY) Table 1: Organisations

Systemic Cytotoxic Therapy in advanced HCC

Systemic Cytotoxic Therapy in advanced HCC Yeul Hong Kim Korea University Anam Hospital Cancer Center Hepatocellular Carcinoma : Overview Epidemiology Current Guideline : advanced HCC Cytotoxic Chemotherapy

Research Article Topotecan and Cyclophosphamide in Adults with Relapsed Sarcoma

Sarcoma Volume 2012, Article ID 749067, 4 pages doi:10.1155/2012/749067 Research Article Topotecan and Cyclophosphamide in Adults with Relapsed Sarcoma P. Blanchette, 1 D. Hogg, 2 P. Ferguson, 3 J. S.

Update on Small Cell Lung Cancer

Welcome to Master Class for Oncologists Session 4: 10:00 AM - 10:45 AM San Francisco, CA October 23, 2009 Speaker: Bruce E. Johnson, MD Professor of Medicine, Dana-Farber Cancer Institute and Harvard Medical

Irinotecan and temozolomide in adults with recurrent sarcoma

ORIGINAL ARTICLE Irinotecan and temozolomide in adults with recurrent sarcoma Phillip S. Blanchette 1, Aaron Lo 2, Pamela Ng 2, Albiruni Razak 3,4, Eitan Amir 4, David Hogg 4, Martin E. Blackstein 3, Abha

PEDIATRIC. BRAIN ACNS 0332: Efficacy of Carboplatin Administered Concomitantly with Radiation and Isotretinoin as a COMPANION STUDIES

PEDIATRIC BRAIN ACNS 0332: Efficacy of Carboplatin Administered Concomitantly with Radiation and Isotretinoin as a Pro-Apoptotic Agent in other than Average Risk Medulloblastoma/PNET Patients. https://clinicaltrials.gov/ct2/show/nct00392327?term=0332&rank=6

High dose chemotherapy in Ewing sarcoma. Nathalie Gaspar Gustave Roussy Cancer Campus, Villejuif (France)

High dose chemotherapy in Ewing sarcoma Nathalie Gaspar Gustave Roussy Cancer Campus, Villejuif (France) Principles of high-dose chemotherapy Log-linear dose/efficacy relation of alkylating agents - Increased

1 The Cancer Programs Regulation (AR 242/98) is amended by this Regulation.

Alberta Regulation 18/2005 Cancer Programs Act AMENDMENT REGULATION Filed: February 22, 2005 For information only: Made by the Minister of Health and Wellness (M.O. 9/2005) on February 17, 2005 pursuant

Local Therapy for Ewing Sarcoma: Current Concepts and Opportunities for Improvement

Local Therapy for Ewing Sarcoma: Current Concepts and Opportunities for Improvement Safia K. Ahmed, MD Department of Radiation Oncology Washington University August 25, 2017 2017 MFMER slide-1 Outline

Considerations for intraperitoneal vs intravenous chemotherapy

Considerations for intraperitoneal vs intravenous chemotherapy Fox Chase Cancer Center, USA Why Invade the Peritoneal Cavity? Because It s s There! Why Invade the Peritoneal Cavity? Is there a true Pharmacokinetic

Haematology, Oncology and Palliative Care Directorate.

Anticancer Treatment for Administration on the Somerset Mobile Chemotherapy Unit The table below details the suitability of different types of anticancer treatment for administration on the Somerset Mobile

Appendix 2. Adjuvant Regimens. AC doxorubin 60 mg/m 2 every 3 weeks x 4 cycles Cyclophosphamide 600 mg/m 2

Appendix 2 Adjuvant Regimens AC doxorubin 60 mg/m 2 every 3 weeks x 4 cycles Cyclophosphamide 600 mg/m 2 CMF IV cyclophosphamide 600 mg/m 2 days 1 & 8 every 4 weeks methotrexate 40 mg/m 2 for 6 cycles

RMS, RMS. (rhabdomyosarcoma,rms) (Intergroup RMS Study Group,IRSG) ( European Pediatric soft tissue sarcomas study group,epssg)

724 2017 10 55 10 Chin J Pediatr, October 2017, Vol.55, No.10 ( CCCG-RMS-2016) (rhabdomyosarcoma,rms), 6.5% [1-3], RMS,, (Intergroup RMS Study Group,IRSG) ( European Pediatric soft tissue sarcomas study

Bevacizumab in Pediatric Patients: How Safe Is It?

Bevacizumab in Pediatric Patients: How Safe Is It? MARIA DEBORA DE PASQUALE, AURORA CASTELLANO, LUIGI DE SIO, CLEMENTINA DE LAURENTIS, ANGELA MASTRONUZZI, ANNALISA SERRA, RAFFAELE COZZA, ALESSANDRO JENKNER

Ovarian Cancer Survival. Ovarian Cancer Follow-up. Ovarian Cancer Treatment. Management of Recurrent Ovarian Carcinoma. 15,520 cancer deaths

Management of Recurrent Ovarian Carcinoma Lee-may Chen, M.D. Department of Obstetrics, Gynecology, & Reproductive Sciences UCSF Comprehensive Cancer Center Ovarian Cancer Survival United States, 28: 1

Paediatric Cancer. Brain. Germ Cell. Embryonic Tumour. Haematology Malignancies. Open. In Development. In Development. Open. Open.

Paediatric Cancer Brain LGG2: Cooperative multicenter study for children and adolescents with Low Grade Glioma GD2: A Phase I/II dose schdule finding study of CH14.18/CHO continuous infusion combined wugt

Protocol Number Tumour Group Protocol Name on NCCP website 22/02/ Lung Afatinib Monotherapy 244 Gastrointestinal Regorafenib Monotherapy

Last Updated 22-Feb-18 Date of last update Protocol Number Tumour Group Protocol Name on NCCP website 22/02/2018 221 Afatinib Monotherapy 244 Gastrointestinal Regorafenib Monotherapy 249 Gynaecology Intrathecal

Protocol Number Intrathecal Methotrexate for CNS 01/02/2018 Prophylaxis in GTN Gynaecology 249

Last updated Feb 9, 2018 Revision due Protocol Name on NCCP website Tumour Group Protocol Number Intrathecal Methotrexate for CNS 01/02/2018 Prophylaxis in GTN Gynaecology 249 Two Day Etoposide CISplatin

Guidelines on Chemotherapy-induced Nausea and Vomiting in Pediatric Cancer Patients

Guidelines on Chemotherapy-induced Nausea Vomiting in Pediatric Cancer Patients COG Supportive Care Endorsed Guidelines Click here to see all the COG Supportive Care Endorsed Guidelines. DISCLAIMER For

Outcome for children with metastatic solid tumors over the last four decades

Washington University School of Medicine Digital Commons@Becker Open Access Publications 2014 Outcome for children with metastatic solid tumors over the last four decades Stephanie M. Perkins Washington

Clinical trials of systemic therapy in osteosarcoma and Ewing s sarcoma: past, present and future

Clinical trials of systemic therapy in osteosarcoma and Ewing s sarcoma: past, present and future Clin. Invest. (2011) 1(10), 1421 1443 Due to multiple factors, including their low incidence, heterogeneity

Neuroblastoma. Elizabeth Roberts. Data Coordinator CIBMTR Data Managers Mentor. Tandem Meeting February 18

Neuroblastoma Elizabeth Roberts Data Coordinator CIBMTR Data Managers Mentor Tandem Meeting February 18 Objectives Know what neuroblastoma is, how it is diagnosed, and how it is treated Complete form 2026:

CCSS Therapy Working Group

CCSS Therapy Working Group Temporally limited, but critical to all aims of the CCSS Immediate tasks: Review and advise on current CCSS MRAF Drugs (doses and exposure) XRT Surgery Develop plans for quality

MASCC Guidelines for Antiemetic control: An update

MASCC / ISOO 17 th International Symposium Supportive Care in Cancer June 30 July 2, 2005 / Geneva, Switzerland MASCC Guidelines for Antiemetic control: An update Sussanne Börjeson, RN, PhD Linköping University,

One Palliative Care Annual Report

One 203 Palliative Care Annual Report One In 202, ASCO released a provisional clinical opinion stating that concurrent palliative care should be considered early in the course of advanced or metastatic

Patient 1: Patient 2:

Appendix A Compiled by Dr. Raymond Ngeh and Dr. Robert Luk Clinical notes and PET/CT scan images of eleven patients: 1. Middle age woman has cancer of the pancreas in the body of the gland. After just

An international strategy to determine the role of high dose therapy in recurrent Wilms tumour

European Journal of Cancer (2013) 49, 194 210 Available at www.sciencedirect.com journalhomepage:www.ejcancer.info Review An international strategy to determine the role of high dose therapy in recurrent

Guidelines for the Use of Anti-Emetics with Chemotherapy

Guidelines for the Use of Anti-Emetics with The purpose of this document is to provide guidance on the rational use of anti-emetics for prevention and treatment of chemotherapy-induced nausea and vomiting

Pass the Buck: The New Face of Oncology Formulary Management

Pass the Buck: The New Face of Oncology Formulary Management June 16, 2016 Agenda U.S. Oncology Market Trends Prescriber Incentive Pathway Overview Oncology TA Deep-Dive Non-Small Cell Lung Cancer Multiple

Disturbances of female reproductive system in survivors of childhood cancer

Disturbances of female reproductive system in survivors of childhood cancer Assoc. Prof. Zana Bumbuliene VU Faculty of Medicine Clinic of Obstetrics and Gynaecology 13 SEP 2014 Introduction Cancer is the

PITFALLS AND TRAPS IN THE DIAGNOSIS AND STAGING OF RENAL TUMOURS OF CHILDHOOD. Gordan M. Vujanić Cardiff, U.K.

PITFALLS AND TRAPS IN THE DIAGNOSIS AND STAGING OF RENAL TUMOURS OF CHILDHOOD Gordan M. Vujanić Cardiff, U.K. RENAL TUMOURS OF CHILDHOOD - CLASSIFICATION (2016) Nephroblastic tumours Mesenchymal tumours

BONE SARCOMA. esmo.org

BONE SARCOMA Stefan Bielack Cooperative Osteosarcoma Study Group COSS Klinikum Stuttgart Olgahospital Pädiatrie 5 (Onkologie, Hämatologie, Immunologie) s.bielack@klinikum-stuttgart.de esmo.org If you

재발성혹은불응성신경모세포종환자에서의활성화 T- 림프구세포치료 2 예

Clinical Pediatric Hematology-Oncology Volume 25 ㆍ Number 2 ㆍ October 2018 CASE REPORT 재발성혹은불응성신경모세포종환자에서의활성화 T- 림프구세포치료 2 예 최정윤ㆍ안홍율ㆍ홍경택ㆍ홍채리ㆍ강형진ㆍ신희영 서울대학교의과대학소아과학교실, 서울대학교암연구소 Two Cases of Adjuvant Immunotherapy

SUPPLEMENTARY INFORMATION

SUPPLEMENTARY NFORMATON n format provided by Melero et al. (AUGUST 2015) Supplementary nformation S3 Combinations including two or more immunotherapy agents based on PD-1/PD-L1 blockade. (Source: https://clinicaltrials.gov/

Open Trials as of end of March 2016

EORTC 10085 PRO EORTC 10085 prospective part, Clinical and biological characterization of Male Breast Cancer: an international EORTC, BIG and NABCG inter study 30 30-Jun-2016 estelle.cassoly@sakk.ch IBCSG

ORIGINAL ARTICLE. Summary. Introduction

Journal of BUON 11: 433-438, 2006 2006 Zerbinis Medical Publications. Printed in Greece ORIGINAL ARTICLE Myeloablative chemotherapy with autologous peripheral blood stem cell transplantation in patients

CHILDHOOD CANCERS are rare, accounting for less than

Regulatory Approvals of Pediatric Oncology Drugs: Previous Experience and New Initiatives By Steven Hirschfeld, Peter T.C. Ho, Malcolm Smith, and Richard Pazdur Purpose: To review the Food and Drug Administration

Chapters from Clinical Oncology

Chapters from Clinical Oncology Lecture notes University of Szeged Faculty of Medicine Department of Oncotherapy 2012. Childhood malignancies The number one cause of death in children is accidents (44%),

18 Week 92% Open Pathway Recovery Plan and Backlog Clearance

18 Week 92% Open Pathway Recovery Plan and Backlog Clearance Page 1 of 6 17.05.2012 1.0 Background 18-Week 92% Open Pathway RECOVERY PLAN The Trust has achieved compliance against the admitted and non-admitted

ASSESSING CHEMOTHERAPY-INDUCED ANEMIA AND ITS

REVIEW Chemotherapy-Induced Anemia in Adults: Incidence and Treatment Jerome E. Groopman, Loretta M. Itri Anemia is a common complication of myelosuppressive chemotherapy that results in a decreased functional

List of Recombinant DNA based Drugs Approved in the Country (Form-45) 1st Jan st Dec 2013

S.No. 1 Name of the firm Ferring Date of Approval 4-Apr-10 License No. Import-450/10 2 G.C.Chemie 23-Jun-10 IMP-572/10 3 R.K. Medicare 9-Sep-10 IMP-783/10 4 5 List of Recombinant DNA based Drugs Approved

Monitoring Metastatic Breast Cancer with Serum HER-2/neu: Individual Patient Profiles

Siemens Healthcare Diagnostics, a global leader in clinical diagnostics, provides healthcare professionals in hospital, reference, and physician office laboratories and point-of-care settings with the

Overview of the Radiation Exposure Doses of the Workers at Fukushima Daiichi Nuclear Power Station

Click here for the corrections made < Reference > December 3, 212 Tokyo Electric Power Company Overview of the Radiation Exposure Doses of the Workers at Fukushima Daiichi Nuclear Power Station * As of

Date : September Permit/License or Registration Application. Permit/License/ Notification/ Registration Description. Remark

Number 1. s 29 Jul 13 N/A Environmental Permit to construct the Passenger Clearance and associated works of the Hong Kong Zhuhai and Macao Bridge Boundary Crossing Facilities EP-353/2009/G 06 Aug 13 N/A

OPEN TRIALS Accruals counted until 30-April Current Accrual

Disease group Breast OPEN TRIALS Trial Title Accrual Target IBCSG 48-14 POSITIVE IBCSG 50-14 OLYMPIA IBCSG 52-15 PALLAS SAKK 21/12 A study evaluating the pregnancy outcomes and safety of interrupting endocrine

Effective local and systemic therapy is necessary for the cure of Ewing tumor Most chemotherapy regimens are a combination of cyclophosphamide,

Ewing Tumor Perez Ewing tumor is the second most common primary tumor of bone in childhood, and also occurs in soft tissues Ewing tumor is uncommon before 8 years of age and after 25 years of age In the

A Review of Ewing Sarcoma Treatment: Is it Still a Subject of Debate?

Send Orders for Reprints to reprints@benthamscience.ae RESEARCH ARTICLE Reviews on Recent Clinical Trials, 2017, 12, 1-5 1 A Review of Ewing Sarcoma Treatment: Is it Still a Subject of Debate? Wala Ben

Trabectedin in ASTS. Le Cesne A, et al. J Clin Oncol. 2018;36(suppl): Abstract

Results of a Prospective Randomized Phase III T-SAR Trial Comparing Trabectedin vs Best Supportive Care (BSC) in Patients With Pretreated Advanced Soft Tissue Sarcoma (ASTS) Abstract 11508 Le Cesne A,

DOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) Therapy (AC-T) 261 CARBOplatin (AUC4-6) Monotherapy-21 days

Last updated Oct 17, 2018 Tumour Group Protocol Number Protocol Name on NCCP website Breast 200 Trastuzumab (IV) Monotherapy 21 days 201 Trastuzumab (IV) Monotherapy 7 days 202 DOCEtaxel Monotherapy 100mg/m2

Case Presentation. Gordon Callender M.D. Surgical Resident

Case Presentation Gordon Callender M.D. Surgical Resident Retroperitoneal Sarcomas Sarcomas Heterogeneous group of rare tumors that arise predominantly from the embryonic mesoderm. Expected incidence for

AHSCT in Hodgkin lymphoma - indication and challenges. Bastian von Tresckow German Hodgkin Study Group Cologne University Hospital

AHSCT in Hodgkin lymphoma - indication and challenges Bastian von Tresckow German Hodgkin Study Group Cologne University Hospital AHSCT in Hodgkin Lymphoma The role of AHSCT in HL Mobilisation failure

IMPLEMENTING RECOVERY ORIENTED CLINICAL SERVICES IN OPIOID TREATMENT PROGRAMS PILOT UPDATE. A Clinical Quality Improvement Program

IMPLEMENTING RECOVERY ORIENTED CLINICAL SERVICES IN OPIOID TREATMENT PROGRAMS PILOT UPDATE A Clinical Quality Improvement Program Today: National completion rates for OTP s hover between 11 14% Retention

<Delete this line and print on hospital headed paper> Euro Ewing 2012

International Randomised Controlled Trial for the Treatment of Newly Diagnosed Ewing's Sarcoma Family of Tumours PARENT INFORMATION SHEET R1 We would

Interim PET Hodgkin s Disease. Fellows talk Fellow: Shweta Jain Faculty: Ajay Gopal

Interim PET Hodgkin s Disease Fellows talk Fellow: Shweta Jain Faculty: Ajay Gopal Why is this a Question? Early Advanced ipet ABVD + RT ABVD Pos Neg ABVD Beacopp Escalation Salvage Deescalation Talk outline

Combining Lurbinectedin and Doxorubicin The UCLH Experience in Small Cell Lung Cancer

Combining Lurbinectedin and Doxorubicin The UCLH Experience in Small Cell Lung Cancer Dr Martin Forster MD PhD Clinical Senior Lecturer in Experimental Cancer Medicine Consultant in Medical Oncology UCL

FGSZ Zrt. from 28 February 2019 till 29 February 2020 AUCTION CALENDAR: YEARLY YEARLY BUNDLED AT CROSS BORDER POINTS

AUCTION CALENDAR: YEARLY YEARLY BUNDLED AT CROSS BORDER POINTS FIRM CAPACITY - First Monday of July 01.06.2019* 01.07.2019 07:00 01.10.2019 04:00 01.10.2020 04:00 2019/2020 01.10.2020 04:00 01.10.2021

SAALT3W Sarcoma Dr. Meg Knowling. Protocol Code Tumour Group Contact Physician

BCCA Protocol Summary for Etoposide, Ifosfamide-Mesna (SAIME) Alternating with vincristine, DOXOrubicin and Cyclophosphamide (with or without Mesna)(SAVAC or SAVACM) with Filgrastim Support at a THREE

COST CONSIDERATIONS Union for International Cancer Control 2014 Review of Cancer Medicines on the WHO List of Essential Medicines!!!!!!!!!

UICCEMLCostingScenarios BackoftheEnvelope Calculations PreparedforWorkingGroupSession:19621November2014,Geneva MethodsSummary We have chosen a conservative approach, calculating cost per vial. We have

Wilms Tumor Outcomes at a Single Institution and Review of Current Management Recommendations

Wilms Tumor Outcomes at a Single Institution and Review of Current Management Recommendations Background: The Duval County Medical Society (DCMS) is proud to provide its members with free continuing medical

SMALL CELL LUNG CANCER Updated Feb 2017 by Dr. Doreen Ezeife (PGY-5 Medical Oncology Resident, University of Calgary)

SMALL CELL LUNG CANCER Updated Feb 2017 by Dr. Doreen Ezeife (PGY-5 Medical Oncology Resident, University of Calgary) Reviewed by Dr. Desiree Hao (Staff Medical Oncologist, University of Calgary) and Dr.

New Treatment Strategies in Osteosarcoma. PD Dr. Claudia Blattmann, Prof. Dr. Stefan Bielack Olgahospital Klinikum Stuttgart Germany

New Treatment Strategies in Osteosarcoma PD Dr. Claudia Blattmann, Prof. Dr. Stefan Bielack Olgahospital Klinikum Stuttgart Germany Introduction Most common bone tumor in children, adolescents and young

Childhood Liver Tumours The SIOPEL experience. Giorgio Perilongo, Clinica Pediatrica, Dipartimento A.I. Di Pediatria di Padova

Childhood Liver Tumours The SIOPEL experience Giorgio Perilongo, Clinica Pediatrica, Dipartimento A.I. Di Pediatria di Padova On behalf of the International Childhood Liver Tumour Strategy Group - SIOPEL

Triple Negative Breast Cancer: Part 2 A Medical Update

Triple Negative Breast Cancer: Part 2 A Medical Update April 29, 2015 Tiffany A. Traina, MD Breast Medicine Service Memorial Sloan Kettering Cancer Center Weill Cornell Medical College Overview What is

The CTR-Test predicts the clinical failure of drug therapy with over 95% accuracy. 1. CTR-Test. Chemotherapy- Resistance-Test

The CTR-Test predicts the clinical failure of drug therapy with over 95% accuracy. 1 CTR-Test Chemotherapy- Resistance-Test Biochemical resistance to chemotherapy is the major impedent to successful treatment.

HRNBL1.7/SIOPEN valid per R4 randomisation activated

Lead Investigator: Study Lead Investigator: Infant issues Lead Investigator: Induction / TVD issues Ruth Ladenstein / Austria Adela Canete / Spain Alberto Garaventa / Italy 2002 February: STUDY activated

Flu Watch. MMWR Week 3: January 14 to January 20, and Deaths. Virologic Surveillance. Influenza-Like Illness Surveillance

Flu Watch MMWR Week 3: January 14 to January 2, 218 All data are provisional and subject to change as more reports are received. Geographic Spread South Carolina reported widespread activity this week.

International Randomised Controlled Trial for the Treatment of Newly Diagnosed Ewing's Sarcoma Family of Tumours. Euro Ewing Version 5.

International Randomised Controlled Trial for the Treatment of Newly Diagnosed Ewing's Sarcoma Family of Tumours Euro Ewing 2012 Version 5.0 2 nd June 2017 Coordinating Sponsor: University of Birmingham

MEDICAL NECESSITY GUIDELINE

PAGE: 1 of 10 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted

Seasonality of influenza activity in Hong Kong and its association with meteorological variations

Seasonality of influenza activity in Hong Kong and its association with meteorological variations Prof. Paul Chan Department of Microbiology The Chinese University of Hong Kong Mr. HY Mok Senior Scientific

Sustained benefits for women with HER2-positive early breast cancer JORGE MADRID BIG GOCCHI PROTOCOLO HERA

Sustained benefits for women with HER2-positive early breast cancer JORGE MADRID BIG GOCCHI PROTOCOLO HERA The fascinating history of Herceptin 1981 1985 1987 1990 1992 1998 2000 2005 2006 2008 2011 Murine

Clinical Tools and Resources for Self-Study and Patient Education

Clinical Tools and Resources for Self-Study and Patient Education CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING CLINICIAN'S RESOURCE GUIDE The clinical tools and resources contained herein are provided as educational

Management of Stage Ic-IV Malignant Ovarian Germ Cell Tumours

Management of Stage Ic-IV Malignant Ovarian Germ Cell Tumours Michael J Seckl Charing Cross Hospital Campus of Imperial College NHS Healthcare Trust Imperial College London, UK 9-12th June 2010 Caravaggio

Form 2023 R2.0: Ovarian Cancer Pre-HSCT Data

Key Fields Sequence Number Date Received: - - CIBMTR Center Number: CIBMTR Recipient ID: Today's Date: - - Date of HSCT for which this form is being completed: - - HSCT type: (check all that apply) Autologous

CANCER PREVENTION AND ACCESS TO MEDICINES. Gracemarie Bricalli ESMO Head of International Affairs

CANCER PREVENTION AND ACCESS TO MEDICINES Gracemarie Bricalli ESMO Head of International Affairs ESMO s 2020 Vision: Access to cancer care ESMO s 2020 vision statement recognises that progress in the management

CancerPACT Cancer Patients Alliance for Clinical Trials

TM CancerPACT Cancer Patients Alliance for Clinical Trials Listing of Ongoing Cancer Clinical Trials in the Sacramento Area Winter 2008 I. Solid Tumors 1. Breast p.1 2. Central Nervous System p.2 3. Gastrointestinal

Flu Watch. MMWR Week 4: January 21 to January 27, and Deaths. Virologic Surveillance. Influenza-Like Illness Surveillance

Flu Watch MMWR Week 4: January 21 to January 27, 218 All data are provisional and subject to change as more reports are received. Geographic Spread South Carolina reported widespread activity this week.

DRAFT FOR PUBLIC CONSULTATION

SEE MYELOMA ELIGIBLE egfr < 30ml/min Multiple myeloma despite correction of hypercalcaemia and dexamethasone? Yes Transplant eligible? Yes SEE MYELOMA- RENAL SEE MYELOMA INELIGIBLE KEY Click to move to

Small Cell Lung Cancer What we have now?

Small Cell Lung Cancer What we have now? Chunxue Bai, M.D., Ph.D. Chair, Chinese Alliance against Lung Cancer Shanghai Respiratory Research Institute Department of Pulmonary Medicine Zhongshan Hospital,

Medical Late Effects of Childhood Cancer

Medical Late Effects of Childhood Cancer Robert Goldsby Associate Professor of Clinical Pediatric UCSF Late Mortality in 5+ Year Survivors 1.00 US Female US Male Survival function estimate 0.70 0.75 0.80

What s new in bone and soft tissue sarcoma Treatment and Guidelines 2012? Rob Grimer

What s new in bone and soft tissue sarcoma Treatment and Guidelines 2012? Rob Grimer ESMO conference 2012 Top Oncologists in world (~ 400) Lots of sarcoma basic science key messages: 40% of STS diagnoses

COME HOME Innovative Oncology Business Solutions, Inc.

Innovative Oncology Business Solutions, Inc. Breast Cancer Diagnostic/Therapeutic Pathway V11, April 2015 Required Structured Data Fields: ICD9 Code Stage Staging Components Performance Status Treatment

Notification to Implement Issued by pcodr: December 14, 2012

PROVINCIAL FUNDING SUMMARY Bendamustine hydrochloride (Treanda) for indolent Non-Hodgkin Lymphoma and Mantle Cell Lymphoma (first-line and relapsed/refractory) perc Recommendation: Recommends For further